MENU CLOSE
About Us

Who We Are

Our Social Responsibility

Events

Exhibitions

Activeties

Members

Hospitals

Individuals

Companies

Member Benefits

 
Bio-medical projectsi

State Key Laboratory of Biotherapy

Cooperation

Achievement Exhibition

Scimea Journals

Signal Transduction and Targeted Therapy

News

News Information

 
Home   >  News
27 Aug 2019
667
Latest News from Member Units | Fluconazole Capsules by Chengdu Brilliant Pharmaceutical Group, The first approved in consistency evaluation in China
Scimea

On February 20, 2019, our company's Fluconazole Capsules were successfully approved for consistency. Our company has carried out comprehensive research into the prescription process, stability, in-vitro dissolution behavior and bioequivalence test of fluconazole capsules. The results show thatour company’s fluconazole capsules are consistent with the original product in terms of quality and therapeutic effect. The approval by the State Drug Administration indicates that the Fluconazole Capsule, another hit product of our company, has been the first to pass the consistency evaluation in China.

 1.jpg1.jpg1.jpg


Product Features

Fluconazole capsules are triazole antifungal drugs for the treatment of Candidiasis, Cryptococcosis and Dermatophytosis. They can also be used to prevent patients susceptible to malignant tumors after cytotoxic chemotherapy or radiotherapy from fungal infections, and treat endemic deep mycosis, Coccidioidomycosis, Coccidioidomycosis, Blastomycosis, Histiocytosis, etc. with normal immune functions.

 



About Chengdu Brilliant Pharmaceutical Group

Founded in 2007, Chengdu Brilliant Pharmaceutical Group is a high-tech enterprise dedicated to the development, production and sales of high-end generic drugs, high-end preparations, innovative drugs and Chinese patent medicines.

For more than a decade, the Group has always adhered to the business philosophy of “Focusing on the pharmaceutical industry development and core competitiveness improvement”, implementing the strategy of combining connotative development with denotative expansion. Internally, the Group attaches great importance to R&D and technology innovation. Externally, it has completed the layout of industrial structure and achieved leap-forward development by virtue of strategic acquisition of target enterprises in the industry. Now the Group has 12 branches (subsidiaries).

At present, having over 3,000 employees, including over 600 R&D personnel, the Group has gradually become a technologically innovative pharmaceutical enterprise with leading R&D capabilities, full range of formulations and varieties, and sound marketing network.


Big News! Sichuan Biotherapy Clinical Medical Research Center Formally Launched
Recap of 2019 China-Japan Advanced Medical and New Drug R&D Summit and Achievements Transformation Conference Available Now!
Spotlight丨Chinese Society for Diseases of the Esophagus Signs a Strategic Cooperation Agreement with Sichuan International Medical Exchange & Promotion Association
[Heroes In White] SCIMEA Invites a Student from West China Hospital, Sichuan University to Compose a Song to Pay Tribute to Frontline Medical Staff
Encounter-Contributed to All Medical Workers Fighting in the Frontline at the Lantern Festival
Latest Events Journals News Members About Us Home
Contact Us

Address: No. 1103-1105, Building 6, S2, Global Center, High-tech Zone, Chengdu

Email: scimea@163.com 

Tel: (0086-)028-63859818   

Fax: (0086-)028-63859818   

Contact: (0086-)19113901604 (wechat:19113901604)


Follow Us
Copyright © 2009-2019 SCIMEA. All rights reserved 蜀ICP备19011649号-1